Novo Nordisk’s oral semaglutide tablet, known as Rybelsus, is gaining popularity in India for treating diabetes and weight reduction. Sales of the drug have more than doubled in the past year. However, doctors have advised against indiscriminate use of the drug. The success of Rybelsus has led to a tripled anti-obesity market in India.
Novo Nordisk A/S will buy Cardior Pharmaceuticals for up to $1 billion, as the Danish pharmaceutical company continues its expansion into cardiovascular disease treatments. Cardior is focused on developing therapies that target microRNA, and the deal includes an upfront payment with additional payouts tied to specific milestones.
Novo Nordisk’s oral semaglutide, used to treat Type 2 diabetes, was launched last year in India.
